Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need.
Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Summit Therapeutics was founded in 2003 and is headquartered in Milton, GB
Summit Therapeutics Locations
Summit Therapeutics Metrics
Summit Therapeutics Summary
Closing share price
Summit Therapeutics's current market capitalization is £98 M.
Summit Therapeutics Financials
We estimate that Summit Therapeutics's revenue is £1.45 M in FY, 2016 which is 32.45% decrease from the previous period.
Revenue growth, %
Summit Therapeutics Market Value History
We estimate that Summit Therapeutics's current employees are approximately 25% female and 75% male.